Innovative Lens Clerio Vision is developing a transformative LIRIC platform that redefines vision correction by altering the refractive index rather than removing or adding material. This positions them as a pioneering partner for advanced eye care providers seeking next-generation solutions beyond traditional LASIK or IOL-based offerings.

ARVO and Wavefront Momentum Active participation and data presentation at ARVO and Wavefront Congress in 2026 signal ongoing clinical validation and visibility. This creates opportunities to align with researchers, early adopters, and clinics that want cutting-edge spectacle-free or contact lens-based corrections to differentiate their practice.

Soft Lens Innovation The announcement of an LCA-correcting soft contact lens and related myopia research opens a pathway to partner with optometry practices and contact lens specialists for new product lines, enhanced patient outcomes, and potential private-label or co-branded opportunities.

Strategic Funding With substantial funding and a revenue stream in the $1M-$10M range, Clerio Vision has capital to scale partnerships, invest in clinical trials, and accelerate distribution channels through eye care distributors and durable medical equipment suppliers.

Targeted Market Fit Operating in medical equipment manufacturing with a focused optics heritage from University of Rochester collaborations positions Clerio Vision to engage ophthalmology clinics, academic centers, and laser surgery centers seeking differentiated technologies and potential integration with existing laser platforms.